## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.7% in mid entry zone (3.0-6.0%), top quartile (81st pct) cross-sectional ranking. Short-term MRS_5 (3.6%) confirms momentum alignment. Strong momentum (+6.4% 5-day acceleration). Outperforming sector by 3.2%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($323.06)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. UnitedHealth Group (UNH) Stock After Hours Today (Dec. 15, 2025): Key News, Analyst Forecasts, and What to Watch Before Tuesday’s Open**
- Source: ts2.tech | 20251216T000848 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) stock saw a modest dip in after-hours trading, influenced by broader industry concerns like rising medical costs and regulatory pressures, highlighted by a rival's downgrade. Investors are advised to watch key macroeconomic data releases on Tuesday morning, including jobs and retail sales reports, as these are expected to heavily impact market sentiment. UNH's next major catalyst will be its full-year 2025 results and 2026 guidance, scheduled for January 27, 2026.

**2. UnitedHealth Group (UNH) Stock News and Forecasts on Dec. 14, 2025: DOJ-Amedisys Deal, Optum Opioid Lawsuit, Earnings Date, and Analyst Targets**
- Source: ts2.tech | 20251214T144652 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) is navigating significant events including a court-approved DOJ settlement for its Amedisys deal, which requires major divestitures, and a fresh legal challenge from West Virginia targeting Optum over alleged opioid oversupply. The company is also preparing for its full-year 2025 earnings release in January 2026, which will include 2026 guidance, and remains a closely watched healthcare stock with varying analyst targets. Investors are balancing the reduced uncertainty from the Amedisys settlement against new litigation risks and ongoing regulatory scrutiny.

**3. Newbridge Financial Services Group Inc. Purchases 5,641 Shares of UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251214T120857 | Bullish | Relevance: 100%
- Newbridge Financial Services Group Inc. significantly increased its stake in UnitedHealth Group Incorporated, purchasing an additional 5,641 shares, bringing their total holdings to 6,399 shares valued at $1.996 million. This move contributes to institutional investors owning approximately 87.86% of UNH. UnitedHealth Group also reported strong quarterly earnings, beating EPS estimates, and declared a quarterly dividend of $2.21 per share.

**4. Key facts: UnitedHealth Group earnings release date set; Themes ETFs launches 2X Long UNH Daily ETF**
- Source: TradingView — Track All Markets | 20251214T010508 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth Group (UNH) has announced an upcoming earnings release. Themes ETFs has launched a 2X Long UNH Daily ETF, aiming to double daily returns for UNH, a stock gaining attention due to Warren Buffett's investment.

**5. St. Louis Financial Planners Asset Management LLC Makes New Investment in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251216T123303 | Bullish | Relevance: 100%
- St. Louis Financial Planners Asset Management LLC has made a new investment in UnitedHealth Group (NYSE:UNH), acquiring 12,542 shares valued at approximately $4.33 million, making it their 7th largest holding. The healthcare conglomerate recently reported Q3 EPS of $2.92, beating estimates, with revenue up 12.2% year-over-year, and declared a quarterly dividend of $2.21. Analyst sentiment remains mixed with a "Hold" consensus rating and a target price of $385.54, though some firms have raised their price objectives.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +6.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Forward P/E 19.2x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $309.0B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | 19.2 |
| Current P/E | 20.9 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.7% to 4.7% (+6.4% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 81st percentile. MRS_5 at 3.6% confirms short-term momentum alignment. Outperforming sector by 3.2pp, stock-specific strength. Below SMA200 (0.95x), long-term trend not supportive. MACD histogram positive (2.51), confirming momentum. RSI neutral at 57. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.67% (CS: 81) | Strong |
| RSI_14 | 57.4 | Neutral |
| MACD Histogram | 2.51 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 0.953x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $341.10
- **Stop Loss:** $323.06 (5.3% risk)
- **Target:** $368.16 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 66
- **Position Value:** $22,512.60
- **Portfolio %:** 22.51%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*